Physician profile
Jurij R Bilyk
NPI 1821098740
$5,818.09
in general payments reported to CMS, 2019-2025
9 companies · $916 in 2025
The $916 reported for 2025 was more than what 76% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,000 · 2023: $42.93 · 2024: $1,859 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Food and Beverage | $318.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,042.93 | 2022-2023 | Tepezza |
| Merck Sharp & Dohme LLC | $2,500.00 | 2024-2025 | |
| Abbvie INC. | $87.52 | 2025 | |
| Biotissue Holdings INC. | $56.98 | 2024 | |
| Alcon Vision LLC | $32.49 | 2025 | Clareon |
| Johnson & Johnson Surgical Vision, INC. | $28.10 | 2024 | Catalys System |
| Ani Pharmaceuticals, INC. | $25.62 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $24.17 | 2024 | Tavneos |
| Merz Pharmaceuticals, LLC | $20.28 | 2025 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jurij Bilyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.